Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired... see more

TSXV:KNE - Post Discussion

Kane Biotech Inc > +Efficacy Results in STEM Pet Oral Care Clinical Trial
View:
Post by StoneMan45 on Mar 10, 2021 8:04am

+Efficacy Results in STEM Pet Oral Care Clinical Trial

https://ir.kanebiotech.com/press-releases/detail/281/kane-biotech-announces-positive-efficacy-results-in-stem

As previously disclosed, two milestone payments to STEM from STEM’s licensing partners are dependent on positive clinical efficacy data and certification from an industry leading body.
Comment by StoneMan45 on Mar 10, 2021 8:13am
Dechra and Animal Care group have milestone payments that can be sizable nd I'm assuming these are the 2
Comment by StoneMan45 on Mar 10, 2021 9:37am
Under the terms of the agreement, Kane Biotech will create a new subsidiary, STEM, in which Animalcare will invest $3 million in installments over a period of 48 months to acquire, on entering into the agreement, a one-third plus one share equity interest. STEM will be established with a global license over Kane Biotech’s existing range of animal health oral care products and in collaboration with ...more  
Comment by francoisl13 on Mar 10, 2021 10:30am
Good work Stoneman, thanks for sharing....
Comment by MirrorWorldMan on Mar 10, 2021 11:34am
All the wheels of this company are turning, the management group is solid with partners in place, products have an exclusive niche, attention is being received from  the US army, research grants in place, deals are transparent, large market, growing revenues, solid financials and a strategic plan in place. Investor awareness is low and desire for new retail stock owners to purchase stock is ...more  
Comment by StoneMan45 on Mar 10, 2021 12:11pm
personally I think Kane is doing an amazing job in all respects so I guess we have different opinions on that . I hate fluff news releases and Kane doesn't do that. I love companies that have a great plan and execute on it and again Kane does that. Excellent at raising non-dilutive funding. No skrewing over of shareholders. Basically one great company and one great buy opportunity. I'm not ...more  
Comment by cleareye on Mar 15, 2021 11:21am
I'm impressed. There's a lot going on with this company. I got in this morning. cleareye.
Comment by StoneMan45 on Mar 15, 2021 11:41am
I fine with the price holding here for a month...
Comment by lscfa on Mar 10, 2021 12:10pm
I'm not a pet owner but I can't imagine any owner likes brushing their pet's teeth.    
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities